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Plasma and bronchoalveolar lavage
samples in acute lung allograft rejection:
the potential role of cytokines as diagnostic
markers
Nicole E. Speck1, Macé M. Schuurmans1, Christian Benden1, Cécile A. Robinson1 and Lars C. Huber2*
Abstract
The role of differential cytology patterns in peripheral blood and bronchoalveolar lavage samples is increasingly
investigated as a potential adjunct to diagnose acute and chronic allograft dysfunction after lung transplantation.
While these profiles might facilitate the diagnosis of acute cellular rejection, low sensitivity and specificity of these
patterns limit direct translation in a clinical setting. In this context, the identification of other biomarkers is needed.
This review article gives an overview of cytokine profiles of plasma and bronchoalveolar lavage samples during acute
cellular rejection. The value of these cytokines in supporting the diagnosis of acute cellular rejection is discussed.
Current findings on the topic are highlighted and experimental settings for future research projects are identified.
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Background
Lung transplantation is an established therapeutic option
for selected patients with end-stage lung disease. While
survival after lung transplantation has increased over time
due to improved survival in the early post-transplant
period, chronic lung allograft dysfunction (CLAD) and in-
fections are the main factors limiting long-term survival
[1] Acute cellular rejection (ACR) is a potential risk factor
for the development of CLAD [2–4]. The gold standard to
detect ACR is histopathological grading of transbronchial
biopsies (TBB). However, these biopsies are invasive and
accurate grading is limited by sampling error and interob-
server variability [5–7]. Furthermore, the clinical relevance
of low grade (A1) rejection is controversial and treatments
vary between centres [8–10].
We have recently reviewed the role of differential
cytology patterns in samples obtained from peripheral
blood (PB) and bronchoalveolar lavage (BAL) for the
development of ACR [11]. While these profiles show
interesting trends that may facilitate early diagnosis and
treatment of ACR, low sensitivity and specificity of these
findings limit the clinical utility and, currently, preclude
the isolated use of cellular patterns for the diagnosis of
ACR. In this context, identification of other biomarkers
is needed to improve the diagnostic performance of
cytokine patterns for diagnosis of AR. We summarise
here the experimental and clinical evidence on cytokine
profiles in BAL and plasma samples during ACR, discuss
limitations and outline areas for future research.
Methods
We searched the electronic databases Medline (Bethesda,
MD, USA: U.S. National Library of Medicine), EMBASE
(Amsterdam, NL: Elsevier B.V.) and Web of Science Core
Collection (New York, NY, USA: Thomson Reuters).
Medical subject heading (MeSH) terms included
“cytokines”, “bronchoalveolar lavage”, “blood plasma”,
“graft rejection” and “lung transplantation”.
Publications were eligible if they provided information
on cytokine patterns in BAL or PB during ACR. We
considered articles published in English until 31 October
2016. This included experimental studies, prospective
and retrospective clinical studies, review articles and
case reports. No other restrictions were applied. We
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then selected those articles that fulfilled our inclusion
criteria. Additionally, we scanned the references of all se-
lected articles to find additional literature that was re-
lated to our research question. Finally, 38 papers were
eligible to be included in our review. A list of the type
and number of articles included is provided in Table 1.
We then evaluated the selected articles and compiled
an extensive table, listing every cytokine, the reference
that mentioned this parameter as well as the observed
data. While writing the review article more papers were
drawn on for background information. Each author
reviewed the entire document and provided input before
the final manuscript was completed.
Cytokines in BAL and plasma samples
Cytokines influence inflammatory and immune reactions
by mediating communication between cells. Cytokines
are cell-derived non-antibody proteins, peptides or gly-
coproteins that activate cells in an autocrine or paracrine
fashion and result in stimulatory or inhibitory effects
[12]. They play a vital role in recruitment, activation,
proliferation or differentiation of regulatory and effector
cells of the immune system [13]. Cytokines can be
divided into six groups according to their functional or
structural similarities (overview provided in Table 2).
While cytokines function in a complex network with a
degree of redundancy, the effects of certain cytokines on
specific cell types are still under investigation [12].
Cytokines influence success and outcome of organ
transplantation substantially [14, 15]. Allograft rejection
is a multifactorial process, resulting from integration of
different components of the immune system [15]. Initial
activation of the innate immune system due to local
tissue damage and ischemia-reperfusion injury might
trigger and amplify the subsequent dysregulation of the
adaptive immune response. Cytokines are produced
during both phases of this process [15]. ACR has been
associated with dysregulated expression of cytokines in
different solid organ transplants [16–18].
Multiple ways to measure and quantify the expression
of cytokines in BAL fluid and plasma samples exist, in-
cluding immunohistochemistry [19], in situ hybridization
[19], real-time polymerase chain reaction (RT-PCR) [20],
enzyme-linked immunosorbent assays (ELISA) [21], flow
cytometry (FCM) [22], bioassays [23], and other immuno-
assays [12]. ELISA allows detection of proteins; the
concentration of the respective molecule can then be in-
terpolated from standard curves. As such, it is the most
frequently used technique [12]. Multi-parameter FCM
allows quantifying many immune cell subsets and cyto-
kine mediators with great flexibility [24]. Among novel
molecular methods, microarrays permit the screening of a
large number of genes, while polymerase chain reaction
(PCR) is more useful to address hypotheses [25].
Many factors can potentially influence the measure-
ments of cytokine levels, and the awareness of these
factors is low [12]. Analysing cytokines in BAL fluid
during rejection is further challenging since the alveolar-
capillary barrier loses integrity and, subsequently, is
more permeable to serum proteins during rejection [14].
Although promising results have been achieved in
several areas of medical investigation, cytokines are not
routinely measured in clinical practice [12, 26]. The
comparability between the above-mentioned methods is
unclear as the influence of various analytical and
Table 1 Types and number of references included in this
review article
Content Study design Number of
studies included
Number of
patients
Number of
samples
Cytokines Experimental 9 - -
Prospective 13 407 1301 BAL
17 serum
Retrospective 12 492 834 BAL
58 serum
Review article 4 - -
Total 38 899 2135 BAL
75 serum
Table 2 Overview of six groups of cytokines
Group Characteristic feature Reference
Interleukin (IL) Large number of cytokines named with a numeric suffix roughly in the
order of discovery or molecular characterization.
[91]
Interferon (IFN) Named for their function to interfere with viral infection, inhibiting viral
replication within host cells.
[92]
Tumor necrosis factor (TNF) superfamily Structurally homologous transmembrane proteins that typically form
homotrimers.
[73]
Transforming growth factor (TGF) superfamily Involved in both tumor development and dissemination. [93]
Colony-stimulating factor (CSF) Stimulate proliferation and expansion of bone marrow progenitor cells,
leading to formation of erythrocytes, granulocytes, monocytes and
lymphocytes.
[94]
Chemokine Structurally homologous, low-molecular weight cytokines that promote
movement and migration of all immune cells between blood and tissue.
[95]
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pre-analytical factors on the results are complex and still
need to be elucidated [12].
Table 3 and Table 4 list several cytokines that are
present in BAL and PB samples. Moreover, anticipated
changes during ACR and both sensitivity and specificity
for the diagnosis of ACR are reported when available.
Figure 1 shows a proposal for an integrative algorithm
with clinical data, radiographic findings, BAL microbiol-
ogy studies, BAL differential cytology and selected
cytokines obtained from BAL and PB samples. Data con-
cerning differential cytology are based on a previous
review article in this journal [11]. Specific constella-
tions in the levels of these factors might increase the
suspicion for ACR. However, standardization of BAL
techniques and detection methods are needed. Appro-
priate cut-off levels can then be determined for
selected parameters to diagnose ACR based on this
algorithmic approach. Cytokines and biomarkers in-
volved are discussed below.
IL-1
Interleukin-1 (IL-1) is a multifunctional pro-inflammatory
cytokine, affecting nearly every cell type [27]. Two genes
for IL-1 exist: IL-1α and IL-1β. In the context of trans-
plantation, IL-1β has been associated with graft-versus-
host disease (GVHD), ischemia-reperfusion-injury and the
development of bronchiolitis obliterans (BO) [28–30].
Clinical studies observed an increase of IL-1 during
periods of ACR. As such, IL-1β was significantly higher
in patients with ACR compared to patients without re-
jection in a prospective study [31]. Moreover, the level
of IL-1β was significantly raised during episodes of rejec-
tion compared to periods before rejection underlining
the potential role of IL-1 as discriminator between rejec-
tion and infection. Another study found that BAL alveo-
lar macrophages (AM) of patients with ACR expressed
significantly more IL-1α and IL-1β compared to lung
transplant recipients without rejection [32].
IL-1 is elevated during ACR and might be a useful marker to distinguish
between allograft rejection and allograft infection.
IL-4
IL-4 is an anti-inflammatory cytokine released by type 2
helper T cells (Th2 cells), basophils and mast cells [33].
While the effects of IL-4 in Th2 cells has been exten-
sively studied, the response to IL-4 in other T cell types
appear to be equally important [33].
Results on IL-4 in clinical studies are inconclusive.
IL-4 could not be detected in AM from BAL samples in
patients with rejection, infection and absence of both
conditions [32]. In another study, the relative amount of
T cells expressing IL-4 did not change between stable
and rejecting groups [34].
Whitehead and colleagues identified IL-4 as a poten-
tially useful marker for ACR [16]. When studying
cytokines in BAL and PB samples from 31 lung trans-
plant recipients, the authors detected IL-4 messenger
RNA (mRNA) in less than 20% of all samples. Interest-
ingly, IL-4 was not found in samples obtained from
patients with infection. The greatest difference was
observed when samples of patients with AR were com-
pared to patients without AR. In addition, cytokine gene
expression levels varied considerably between PB and
BAL samples. This observation was confirmed in
another study, where T cell cytokine production in BAL
and PB was compared in stable lung transplant recipi-
ents and healthy volunteers [35]. In both groups, T cells
(CD4+ and CD8+) produced significantly more IL-4 in
BAL compared with PB. Furthermore, CD8+ T cells in
BAL expressed significantly more IL-4 in transplant re-
cipients than in healthy controls.
Expression of IL-4 during ACR is unclear. IL-4 might not be found in lung
transplant recipients with infection.
IL-6
IL-6 is one of the major pro-inflammatory cytokines that
mediates hepatic acute-phase response [36]. In the lungs,
IL-6 has been identified as a key player in vascular remod-
elling and pulmonary hypertension (reviewed in [37]).
The pro-inflammatory role of IL-6 in ACR has been
investigated in both experimental and clinical studies.
Rolfe and colleagues observed a bimodal pattern of
IL-6 production in BAL fluid in an experimental in
vivo model [38]. The investigators transplanted in-
compatible left lung allografts from Brown Norway
rats into Lewis rats. IL-6 mRNA levels were increased
in BAL fluid of the transplanted lung on day one and
were decreased by day four before increasing again
on day six compared to the native lung. The observed
pattern coincided with histopathologic changes con-
sistent with ACR.
IL-6 tends to be increased in BAL samples during
ACR. As such, IL-6 was elevated during ACR in a re-
cent prospective study [31]. However, this increase
was not significant and it is of note that diagnosis of
ACR was not based on TBB but on clinical and
radiological criteria. IL-6 was also increased in BAL
samples during ACR in another clinical study [16].
IL-6 and IL-4 increases were found more often in pa-
tients with ACR than any other cytokines changes.
Similarly, IL-6 protein was higher in lung transplant
recipients with histopathogical proven ACR compared
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Table 3 Observed expression of cytokines in BAL samples during ACR
Cytokine Expression in BAL Reference Measure Sensitivity
PPV
Specificity
NPV
IFN- γ ↑ [55] mRNA; during early ACR only
↑ [40, 56] mRNA 77.7%
73.6%
85.7%
88.2%
↑ [71] Total RNA
0 [41] mRNA
- [72] mRNA
TNF- α ↑ [38, 69, 74] mRNA (experimental)
↑0 [31] Protein
0 [41] mRNA
↓ [96] mRNA expressed by AM
↑ [43] mRNA expressed by AM
0 [97] mRNA expressed by mononuclear cells
TGF-β - [71] mRNA
↓…↑ mRNA expressed by AM; dramatic increase
15 days after onset of ACR
IL-1 ↑ [31] Protein
↑ [32] mRNA expressed by AM
IL-2 0 [55, 56] mRNA 44.4%
40.0%
63.6%
67.7%
- [32] mRNA expressed by AM
IL-4 ↑ [16] mRNA
↑ [35] mRNA expressed by CD8+ T cells
0 [34] mRNA expressed by T cells
- [32] mRNA expressed by AM
IL-5 0 [98] Protein
IL-6 ↑ [38, 99] mRNA (experimental)
↑ [16] mRNA
↑ [40] Protein
↑0 [31] Protein
0 [41] mRNA
0 [42] Protein
↑ [32] mRNA expressed by AM
↑0 [43, 44] mRNA expressed by AM
IL-8 ↑0 [31, 50] Protein
0 [51] Protein and mRNA
0 [42] Protein
IL-10 ↑ [31] Protein
0 [55, 56] mRNA 88.8%
41.0%
32.3%
84.6%
IL-15 ↑ [32, 61] mRNA expressed by AM
↑ [62] Blocked IL-2 receptor
0 [41] mRNA
IL-16 (↓) [100] Protein
(↑) [41] mRNA
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with infection and levels of IL-6 were significantly
increased during moderate or severe ACR [39]. In
another study, IL-6 mRNA in BAL was highest in
patients with corticosteroid-refractory histologic
ACR [40].
Conversely, other studies found no significant
association between IL-6 and ACR [41, 42].
Various researchers have investigated the expression of
IL-6 by AM. Production of IL-6 by AM in BAL fluid
was significantly increased during ACR compared to
stable control patients [43, 44]. When BAL was repeated
15 days later, values had decreased, reaching similar
levels as in stable control patients [43]. Furthermore,
cytokine production was higher during symptomatic
rejection episodes compared to silent rejection episodes
and in ISHLT Grade II rejection compared to Grade I
rejection. However, both differences were not significant.
Similarly, in another study, AM secreted significantly
more IL-6 during ACR than in patients without rejection
or infection [32].
Monitoring IL-6 in serum after lung transplantation
might be beneficial to detect ACR. However, level of evi-
dence is low. Yoshida and colleagues found that a spiked
elevation of IL-6 might predict the presence of ACR
[45]. The investigators divided 17 patients into four
groups according to the pattern of IL-6 elevation. 13 out
of 19 spikes in the group with sharp raises of serum IL-6
levels were associated with histologically or clinically
confirmed ACR. Conversely, continuously high levels of
IL-6 were characteristic for infection. In another study,
IL-6 was increased in serum during ACR, though this
was not significant [46]. Interestingly, no association was
found between the levels of IL-6 in serum and BAL.
Increased IL-6 has been associated with ACR. Monitoring serum levels of
IL-6 after lung transplantation might help to detect ACR. However,
current level of evidence is low.
IL-8
IL-8 is a major chemotactic factor for neutrophils
secreted by macrophages and respiratory epithelial cells
[47]. In the lung, IL-8 is associated with lymphocytic
airway inflammation and neutrophilic reversible allograft
dysfunction (NRAD) [48, 49].
Some clinical studies have identified an increase of
IL-8 in BAL fluid during ACR, yet this was not
significant [31, 50]. Levels of IL-8 did not correlate with
severity of ACR [50].
Other investigators did not notice any significant
changes between nine rejecting patients and 17 non-
rejecting controls as far as levels of IL-8 in BAL were
concerned [51]. In a case–control study no significant
difference was detected between IL-8 levels in BAL fluid
of patients with ACR and stable controls [42]. While IL-
8 has been clearly linked with CLAD, its role in ACR
has yet to be elucidated.
IL-8 has been associated with the development of BO, but a defined
role of IL-8 in ACR has yet to be elucidated.
IL-10
IL-10 is an anti-inflammatory cytokine secreted by Th 2
cells and regulatory T cells. It attenuates inflammatory
response by inhibition of T cells, monocytes and
macrophages [52]. Several experimental in vivo studies
showed that administration of IL-10 before transplant-
ation improved graft acceptance and survival [53, 54].
Table 3 Observed expression of cytokines in BAL samples during ACR (Continued)
IL-17 ↑ [51, 66] Protein
↑ [51] mRNA
0 [41] mRNA
IL-18 0 [101] Protein
CXCL10 ↑ [39, 41] mRNA
↑ [80] Protein
0 Unchanged
↑ Increased
↓ Decreased
↑0 Increased without statistical significance
() Confounded effect
- Not detected
Table 4 Observed expression of cytokines in plasma samples
during ACR
Cytokine Expression in serum Reference Remark
IL-6 ↑ [45] Spiked elevation
↑0 [46]
↑ Increased
↑0 Increased without statistical significance
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Importantly, this effect was not observed when IL-10 was
given post transplantation.
Clinical data on IL-10 in BAL are conflicting. IL-10
mRNA was found in most BAL samples of patients who
had undergone lung transplantation, irrespective of
whether or not ACR was diagnosed [55]. Similarly, levels
of IL-10 mRNA did not correlate with ACR in another
study, as this cytokine was present in most BAL samples
regardless of whether or not ACR was present [56]. In
contrast, Patella and colleagues detected an increase of
IL-10 levels in BAL fluid during ACR compared to infec-
tion and baseline [31]. Interestingly, levels of IL-10
showed opposite trends during infection and ACR.
While levels of IL-10 increased during ACR, the expres-
sion of IL-10 was low during bacterial and CMV
infection.
IL-10 has been attributed a protective role against
allograft rejection, as highlighted by lung biopsies from
clinical and experimental studies [57, 58]. Zheng and
co-workers observed that patients with an increased IL-
10 production genotype were less likely to have two or
more consecutive biopsy specimens of ≥ ISHLT Grade A2
rejection despite anti-rejection treatment (steroid bolus,
steroid taper or anti-T cell globulin) during the first year
post transplantation compared with intermediate or de-
creased IL-10 production genotypes [57]. The authors
suggested that future genetic testing might help to identify
patients at risk for multiple episodes of ACR, which might
help to tailor therapeutic regimens. The balance between
graft destruction and regulation determines graft survival
[59]. Regulatory immune cells in a recipient can shift the
balance towards graft survival. Interestingly, one of the
common features of many regulatory cells is their ability
to secrete IL-10 [59]. The observed increase of IL-10
during ACR might thus reflect the attempt to create an
anti-rejection microenvironment.
Using a rat model, Oishi and co-workers assessed the
effect of ex vivo lipid-mediated transbronchial human
IL-10 gene transfer [58] and examined the intra-graft
cytokine profile on day three and six after single-lung
transplantation between highly histo-incompatible rats.
The stage of ACR and different pathologic markers for
inflammation were lower in the group receiving intra-
bronchial plasmids encoding IL-10 compared to the
control group receiving mock plasmids. Furthermore, ex
vivo lipid-mediated transbronchial human IL-10 gene
transfer was associated with lower levels of IL-2 and
TNF-α mRNA on day three post transplantation [58].
Fig. 1 Proposal of an integrative algorithm. This descriptive algorithm is designed to estimate probabilities for ACR or other causes of ALAD in lung
transplant recipients presenting with clinical findings or a drop in lung function (FEV1 > 10%). The integration of microbiology data, differential cytology
[11] and cytokine expression levels from peripheral blood and BAL samples might assist in decision-making to increase or decrease the likelihood for ACR
in the context of the clinical presentation. In the absence of standardized BAL techniques and detection methods, BAL cytokine expression levels and cut--
offs have to interpreted wth caution and should be confirmed in larger studies. Since results from studies with very different designs have been included,
direct translation in a clinical setting is not feasible and the use of this algorithm does not obviate the need for biopsy to confirm or exclude histology-
proven ACR. * Numbers vary between different studies. ** Absence of microbiological evidence for infection
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Increased IL-10 has been attributed a protective role against inflamma-
tion. BAL levels show no clear consistent pattern. However, IL-10 levels
increased in ACR and decreased in infection in one study.
IL-15
IL-15 is a pro-inflammatory cytokine secreted by mul-
tiple tissues and cell types, among which macrophages
play a principal role [60]. IL-15 is similar to IL-2 in its
structure and biological function. It is a potent chemo-
attractant factor for T cells and is involved in B cell mat-
uration and NK cell cytotoxicity [60].
The few results on levels of IL-15 in BAL are promising
in the context of ACR. According to Rizzo and colleagues,
IL-15 expression by BAL-derived AM was increased in
five out of nine patients experiencing ACR compared to
patients without rejection and infection [32]. In the other
four patients with ACR no IL-15 was detected. In the
same study, the authors prospectively assessed cytokines
in three patients during and after treatment of ACR,
noticing that levels of IL-15 decreased with resolution of
ACR. Shi and co-workers found a similar trend: IL-15
mRNA expressed by BAL AM was significantly higher in
15 patients with ACR than in 19 stable controls [61]. In
another study, IL-15 protein was elevated in BAL during
ACR when the IL-2 receptor was blocked [62]. This study
was conducted based on the assumption that IL-2 and IL-
15 share similar functions and on the observation that
blocked IL-2 receptors do not completely avert ACR.
Three interesting observations were made: The average
IL-15 protein level was increased in acutely rejecting
patients compared to stable controls, IL-15 was distrib-
uted in a bimodal fashion in patients undergoing ACR,
and levels of IL-15 did not correlate with infection. In
contrast to the trends mentioned above, Husain and
colleagues did not find any significant association between
IL-15 and ACR [41].
Elevated IL-15 expressed by AM has been associated with ACR. When
the alpha chain subunit of the IL-2 receptor was blocked IL-15 was
increased.
IL-17
IL-17 is a pro-inflammatory cytokine, which is primarily
secreted by CD4+ T cells [63]. IL-17 has been reported
to play an important role in sustained mobilisation of
neutrophils via induction of IL-8 [64]. In this context, it
has been linked with chronic inflammatory lung
diseases, although its causative role is unclear [65].
Various studies have suggested a role for IL-17 in
acute and chronic rejection after lung transplantation
[51, 66, 67]. Vanaudenaerde and co-workers found an
increase of IL-17 in BAL fluid during ACR on day 28
after lung transplantation [51]. IL-17 mRNA was raised
significantly compared to stable controls. IL-17 protein
was also increased, however, without reaching
significance. At the same time, raised IL-17 protein
levels were associated with higher lymphocytes in BAL
fluid. Interestingly, IL-17 protein correlated with severity
of rejection. When BAL fluid was analysed on day 90
after transplantation, IL-17 was no longer elevated com-
pared with stable control patients. It remains unclear
whether this finding is due to immunosuppressive
therapy or whether it represents the natural course after
ACR. Conversely, Husain and colleagues did not find
any association between IL-17 levels and ACR [41].
IL-17 has been associated with mobilisation of neutrophils and chronic
inflammatory lung disease. Levels of IL-17 were increased in BAL during ACR.
IFN-γ
Interferon gamma (IFN-γ) is a pro-inflammatory cyto-
kine secreted by type 1 helper T cells (Th1 cells) and
natural killer cells (NK cells) in response to IL-12 from
macrophages. It promotes macrophages to degrade
phagocytosed pathogens and inhibits differentiation of
Th2 cells [68]. It is further involved in NK cell activity
and B cell regulation [68].
IFN-γ was found to be raised in animal models during
ACR [69, 70]. In a rat model, Brown Norway rat lungs
were depleted of AM before transplantation into Lewis
rats [70]. While production of IFN-γ was significantly
reduced in BAL fluid after transplantation, the develop-
ment of ACR could not be prevented.
Results obtained in clinical studies remain
inconclusive. Expression of IFN-γ mRNA in BAL fluid
has been associated with ACR in several studies [55, 56].
In a prospective study mRNA expression of IFN-γ in
BAL fluid was significantly higher during early ACR
(defined by occurrence within three months following
transplantation) but not during late ACR [55]. In
another study, the presence of IFN-γ in BAL fluid pre-
dicted ACR with a specificity of 85.7% and a sensitivity
of 77.7% (positive predictive value (PPV) 73.6%, negative
predictive value (NPV) 88.2%) [56]. Moreover, when
IFN-γ gene was expressed during ACR, FEV1 declined
more than in the absence of IFN-γ expression. In
another study, BAL cell-derived IFN-γ mRNA was
highest in patients with refractory ACR that did not
respond to high-dose intravenous corticosteroid therapy
compared to non-rejecting or steroid-responsive
control-groups [40]. After treatment with aerosolized
cyclosporine IFN- γ decreased significantly [40]. By
performing gene expression microarrays, IFN-γ was found
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to be elevated in all seven samples with ACR whereas it
was decreased or absent in the other 27 non-rejection
samples [71].
Other studies found no significant association between
IFN-γ and ACR or failed to detect IFN-γ mRNA in BAL
samples from patients with ACR [41, 72].
IFN-γ has been found at increased levels in BAL samples during ACR.
TNF-α
Tumor necrosis factor alpha (TNF-α) is a potent pro-
inflammatory cytokine secreted by macrophages, T cells
and NK cells that directs homeostatic and pathogenic
functions [73].
TNF-α was increased in animal models during ACR
[38, 69, 74]. More specifically, TNF-α was raised at cellu-
lar and molecular levels in BAL samples of a rat model
[74]. Production of TNF-α mRNA was highest during
severe ACR. Moreover, the extent of the bioactivity of
TNF-α was shown to correlate with the histopatho-
logical grade of rejection. Interestingly, animals receiving
intravenous injections with TNF-α antisera before trans-
plantation showed markedly attenuated ACR compared
with rats receiving control sera [74]. In another experi-
mental study, donor rat lung allografts (Brown Norway)
that had been depleted of AM before transplantation
into recipients of a different strand (Lewis) showed
significantly lower levels of TNF-α compared with
untreated donor lungs in BAL fluid [70]. While this de-
pletion affected the production of several IgG subclasses,
it did not prevent the development of ACR.
Data obtained by clinical studies remain unclear.
Husain and colleagues found no significant association
between the expression TNF-α in BAL fluid and ACR in
a prospective study [41]. The authors explained this by
the low levels of TNF-α in the BAL samples, probably
due to the lower number of AM detected.
In a previous study that analysed levels of TNF-α RNA
in 26 BAL and TBB samples, TNF-α was expressed
primarily in inflammation due to unspecified causes and
less in ACR [72]. Conversely, Patella and colleagues
reported an increased expression of TNF-α during ACR,
however this finding was not significant [31].
Inconsistent results between studies analysing the
expression of TNF-α by AM in BAL might be explained
by different methods for culturing macrophages and lack
of standardization. However, studies on biomaterials did
not show relevant differences in cytokine expression
from macrophages by different surface chemistries used
to culture these cells [75]. TNF-α was significantly
increased in the culture of BAL AM during ACR
compared to clinically stable periods [43]. Also, cytokine
levels were higher during symptomatic periods of ACR
and in ISHLT Grade II rejection compared to asymp-
tomatic periods and grade I rejection, respectively. In
BAL samples analysed 15 days after ACR, TNF-α levels
had decreased and were comparable to the levels of
patients without rejection. In another study AM
expressed TNF-α in five out of nine patients during
ACR, while TNF-α could not be detected in the
remaining four patients [32]. Another study found
contrasting results; TNF-α secretion was significantly
lower during ACR compared to levels in patients with
no complication or infection after transplantation [76].
TNF-α levels were increased in BAL samples of experimental models
mimicking ACR. Data in human lung transplant recipients are less clear.
TGF-β
Transforming growth factor beta (TGF-β) is an anti-
inflammatory cytokine also known for its profibrotic role
[77]. Dysfunction of TGF-β has been observed in
autoimmune diseases or in in conditions with impaired
immune surveillance [78]. Among the three isoforms
TGF-β1, −β2 and -β3 found in mammals, TGF-β1 pre-
dominates with strong immune-regulatory properties [79].
Increased TGF-β has been linked to the late phase of
ACR and tissue repair during an inflammatory reaction.
Magnan and colleagues examined the secretion of IL-6
and TGF-β by AM during ACR and other complications
after lung transplantation [44]. Interestingly, the
secretion of IL-6 and TGF-β by AM showed an opposite
trend with time: IL-6 was elevated at the onset of ACR
and returned to control values 15 days after diagnosis of
AR and treatment. Conversely, the average concentra-
tion of TGF-β in AM supernatants was normal at the
beginning and increased dramatically by 15 days after
onset of ACR. This observation mirrors the inflamma-
tory reaction in lung tissue, characterised by a phase of
lung injury, followed by a phase of tissue repair.
In another study that used gene expression
microarrays to identify new biomarkers for ACR, TGF-β
was not found to be up-regulated [71]. However, many
downstream mediators were increased, including the
TGF-β receptor.
TGF-β has been associated with the phase of tissue repair and was
significantly increased 15 days following ACR and treatment in one
study.
CXCL10
CXCL10 is a chemokine induced by IFN-γ. It has been
shown to promote the directional migration of activated
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T cells during inflammatory immune responses [80].
CXCL10 has been strongly associated with graft survival
after transplantation of various organs, including kidney,
heart and GVHD [81].
Increased CXCL10 has been associated with ACR in
clinical studies [39, 41]. CXCL-10 was higher in patients
with ACR than in patients with infection [41]. This find-
ing might help differentiate ACR from infection in trans-
plant recipients with deterioration of graft function.
Agostini and colleagues identified a correlation between
high levels of CXCL10 protein in BAL and early ACR
(ISHLT Grade A1-A3) and late rejection [80]. The
authors furthermore emphasised that CXCL10 and its
receptor CXCR3 might provide suitable molecular
targets to decrease T cell recruitment and inhibit T cell-
specific inflammatory processes in the lung. In another
study, cumulative exposure of lung allograft recipients to
CXCL10 correlated with a significant risk of graft failure
[82]. CXCL10 was also elevated before the onset of BO.
CXCL-10 might not be specific for rejection processes,
as it has also been detected in lungs with sarcoid granu-
lomatous reactions [83].
Elevated levels of CXCL10 have been found in several clinical studies
during ACR. The use of CXCL10 as diagnostic marker (or its receptor
CXCR3 as therapeutic target) might be limited by the lack of specificity
for allograft rejection.
Summary
Studies about the level of cytokines in BAL during ACR
show inconsistent results. This is probably due to
discrepancies between BAL techniques, laboratory
methods and the complexity of the cytokine network.
Nevertheless, changes in cytokine expression have been
observed in BAL samples during ACR, among which an
increase in IL-1, IL-6, IL-15, IL-17 and CXCL10 seems
most consistent.
Few studies assessed cytokine levels in serum. A sharp
increase in serum IL-6 seems to be associated with ACR.
The scarcity of serum data is likely due to the on-going
controversy whether pathological changes in a solid
organ of the body are accurately reflected by blood
mediators assessed in the systemic circulation [14, 24].
Limitations
Data from the studies included in this review should
be interpreted with caution. Seriously diverging
methodologies impair direct comparison between studies
and might explain discrepancies in the cytokine profiles
between various laboratories investigating the same
molecules [11, 12].
At present, measurements of cytokine levels in BAL
samples are not standard of care in lung transplant
patients. Different BAL techniques and several sampling
issues limit the direct comparability of BAL results [84, 85].
More specifically, the composition of BAL fluid is
influenced by dilution factors related to the BAL
technique, alveolar permeability at the time of sampling
and contamination by bronchial fluid [85, 86]. Moreover,
pattern and volume of instilled fluid are important
issues and might alter cytokine levels. The ISHLT has
recently established a working group on BAL
standardization to address these issues in the context
of lung transplantation [Tereza Martinu, Toronto,
Canada, personal communication].
Furthermore, cytokine detection methods lack
standardization and reproducibility [12, 87]. ELISAs are
currently the preferred method to measure cytokine
levels as outlined above [12]. However, sensitivity of
different ELISA kits and reproducibility within the same
kit vary substantially, resulting in a wide variation of
values [88, 89].
Few of the cytokines described in this article have
been investigated in a prospective validation study,
moreover, data on the levels of healthy controls are rare
and no threshold levels have been set for ACR after lung
transplantation. Consequently, such cut-off levels should
be defined and sensitivity, specificity and predictive
values should then be established in a multi-centre
cohort study.
All these factors limit comparability, conclusions and
direct translation of these findings into a clinical setting.
For future research it is imperative that the methods to
identify potential biomarkers of ACR are standardised
and validated. Potential molecules should then be
assessed prospectively in multi-centre studies with large
cohorts, using consistent, validated methods.
Standardized retrieval and detection methods would
ultimately allow reliable data analysis and integration.
Considering the pleiotropic nature and redundancy of
cytokines, creating a composite score that integrates
several cytokines will enhance the diagnostic value of
the BAL cytokine profile. Cytokine patterns could
further be merged with changes in cellularity to increase
sensitivity and specificity, as seen in the context of
CLAD [42]. However, data complexity will make
translation into a clinical setting more challenging.
Conclusions
Changes in cytokines of BAL and plasma samples during
ACR in the lung have been identified. Whereas an
increase in IL-1, IL-6, IL-15, IL-17 and CXCL10 in BAL
fluid might warrant suspicion for ACR, levels of IL-8
and IL-18 do not appear to be suitable as diagnostic
markers during ACR. Data from blood analysis remain
weak with very few studies assessing cytokine changes in
PB during ACR. A spiked elevation of IL-6 has been
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associated with ACR. Overall, no strong associations
were found that would allow relying exclusively on single
cytokine profile changes in BAL or PB samples for
diagnosis of ACR. Combinations of cytokine alterations
may eventually contribute to a composite score drawing
from more than one marker setting (BAL and PB
cytokines and cytology), which may increase diagnostic
accuracy and clinical use.
The proposed algorithm in Fig. 1 integrates different
clinical data to increase the likelihood for ACR and
warrant bronchoscopy to obtain biopsies. It has to be
reminded, however, that even TBB and BAL results have
limitations for detecting rejection and infection and
other causes of allograft dysfunction have always to be
considered.
To strengthen the reproducibility of this data it might
be beneficial to routinely measure protein levels of IL-1,
IL-6, IL-15, IL-17 and CXCL10 when performing BAL
analyses during bronchoscopy of asymptomatic patients
as well as in patients with suspicion of ACR and other
pathologies of the lung and airways. Blood samples
could be routinely screened for levels of IL-6 protein.
This will allow defining a normal cytokine profile in
BAL and PB as well as cut-off values for ACR, as shown
in the context of BAL cytology [90].
Advancing research on non-invasive biomarkers may
eventually improve patient care. Using less-invasive
assays will help to i) detect ACR at an earlier stage, ii)
determine subclinical rejection, iii) develop drugs target-
ing specific molecular structures, iv) identify allograft
recipients who benefit from reduction or modification of
immunosuppressive drugs and v) recognize patients at
risk for CLAD not identified by TBB [8].
So far cytokine profile analysis is not part of the
routine diagnostic workup for suspected ACR. When
used within the clinical context, cytokine and cytology
profiles of BAL and serum samples might be useful to
assist in decision-making and alter the likelihood for the
presence or absence of ACR. Overall, BAL and serum
samples are no substitutes for TBBs in the evaluation of
lung function decline in lung transplant recipients, but
may increase the diagnostic yield of bronchoscopy for
detection of ACR.
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